HomeAI · summaries
Storia in 4 fonti
Berobenatide shows promise for monthly GLP-1 dosing
NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or overweight, with and without type 2 diabetes.Both weekly and monthly dosing was feasible and well tolerated, researchers reported during a symposium at the American Diabetes Association Scientific Sessions.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented…
- ·
morningstar.com
Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
